Logo
faq question Joey Med

Switching From Semaglutide to Tirzepatide in 2026: What a New Study of 20,000 Patients Found

MD Telehealth Platform LLC DBA Joey Med is committed to protecting your health information in compliance with HIPAA regulations.
By Joey Med
5 min read
Published:
New Cleveland Clinic data on 20,486 patients: switching between semaglutide and tirzepatide was linked to 16% weight loss over two years — and quitting treatment cost the most. Here's what it means.

New Cleveland Clinic data on 20,486 patients: switching between semaglutide and tirzepatide was linked to 16% weight loss over two years — and quitting treatment cost the most. Here's what it means.

Overview

If you've been on a GLP-1 medication for a while and the scale has slowed — or your insurance, your side effects, or your budget is forcing a change — you've probably asked the question: should I switch to the other one? New research presented this week finally puts real numbers behind the answer. A Cleveland Clinic study of 20,486 patients, presented at ObesityWeek 2026 on November 15 and published in the journal eClinicalMedicine, compared five different paths patients took after starting semaglutide or tirzepatide — and found that switching between the two medications was linked to about 16% total body weight loss over two years, substantially more than staying on the original drug, and four times more than stopping treatment altogether.

Here's what the study showed, which direction of switch worked better, and how to think about it if you're weighing a change in your own treatment.

What the New Cleveland Clinic Study Looked At

Researchers led by Hamlet Gasoyan, PhD, of Cleveland Clinic's Center for Value-Based Care Research analyzed electronic health records from 20,486 adults who took once-weekly injectable semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for at least three months, starting between 2021 and 2023. According to Healio's report on the ObesityWeek presentation, the average patient was about 57 years old, 63% were women, roughly two-thirds had type 2 diabetes, and 73.4% started on semaglutide.

The team then tracked what patients actually did next and sorted them into five strategies: staying on their original medication, switching between semaglutide and tirzepatide, switching to a different weight loss medication (such as liraglutide, phentermine-topiramate, or naltrexone-bupropion), undergoing bariatric surgery, or stopping treatment entirely with no further medical or surgical care.

The Results: Staying in Treatment Paid Off — Quitting Cost the Most

At the two-year mark, the average total body weight loss lined up in a clear hierarchy. Bariatric surgery led with roughly 28%. Switching between semaglutide and tirzepatide came next at about 16%. Staying on the original medication produced nearly 11%. Switching to a different (non-GLP-1) obesity medication yielded about 8%. And patients who stopped treatment without any replacement kept off only about 4%.

Improvements in blood sugar and blood pressure followed the same pattern: the strategies that kept patients in active treatment delivered meaningfully better cardiometabolic results than stopping, which produced minimal improvement.

"When a patient stops a GLP-1 medication, the most important question is what comes next," said study co-author Dr. Ali Aminian, director of Cleveland Clinic's Bariatric and Metabolic Institute. Gasoyan put it more bluntly: needing to stop an injectable GLP-1 "does not mean that their obesity treatment journey has to end."

Which Direction of Switch Worked Better?

The headline 16% figure averages both directions, but the details matter. Per Healio's coverage, patients who moved from semaglutide to tirzepatide lost about 3 kg (6.6 lb) more than comparable patients who stayed on semaglutide. The reverse was not true: among patients who started on tirzepatide, staying on it was associated with about 4.5 kg (9.9 lb) more weight loss than switching to semaglutide.

That asymmetry fits what head-to-head trial data has already suggested — tirzepatide, which activates both GIP and GLP-1 receptors, tends to produce greater average weight loss than semaglutide. So for patients plateauing on semaglutide, stepping up to tirzepatide has real support in the data. Moving the other way is usually driven by cost, availability, or tolerability rather than efficacy — legitimate reasons, but worth an honest conversation with your provider about the trade-off.

Why People Switch or Stop in the First Place

GLP-1 use has exploded — Gallup polling cited by Cleveland Clinic found that 11% of U.S. adults were using these medications for weight loss in 2026, up from 3% in 2024 — and so have the frictions that push people off treatment. Cost and insurance are the big ones: a separate analysis presented at the same conference found that 35.7% of nearly 70,000 initial prior authorization requests for obesity medications among commercially insured adults were denied.

Side effects are the other major driver. Gastrointestinal issues — nausea, vomiting, constipation — remain the most common reason patients quit, and they often flare during dose escalation. Before abandoning an otherwise effective medication, it's worth knowing these symptoms can frequently be managed with slower titration and supportive treatment like anti-nausea medication prescribed alongside your GLP-1.

What This Means for Your Treatment Decisions

A few honest caveats. This was an observational study from a single health system, not a randomized trial — patients who switched medications or chose surgery may differ from those who stopped in ways records can't fully capture, like insurance coverage, income, or motivation. The findings show strong associations, not proof of cause and effect. And bariatric surgery, while the most effective option on average, involves eligibility criteria, recovery, and risks that make it the right choice for some patients and not others.

But the practical takeaway is hard to miss: obesity behaves like the chronic disease it is, and the patients who did best were the ones who stayed in some form of active treatment. If your current medication has stalled, become unaffordable, or caused side effects you can't live with, the data says your best move is to adjust the plan with a licensed provider — not to walk away from treatment entirely.

How to Get Started With JoeyMed

If you're considering a switch — or starting GLP-1 treatment for the first time — JoeyMed makes the conversation easy. Our licensed providers review your health history, current medications, and goals through a simple online visit, and can determine whether compounded tirzepatide or another option fits your situation, including screening for contraindications like a personal or family history of medullary thyroid carcinoma or MEN 2.

Every treatment plan includes ongoing provider support, so if you plateau, struggle with side effects, or need to adjust your dose, you're adjusting with medical guidance instead of guessing on your own. Explore our weight loss program to see if treatment is right for you — because as this week's data shows, the plan that keeps you in treatment is the plan that works.

Switching From Semaglutide to Tirzepatide in 2026: What a New Study of 20,000 Patients Found | Joey Med Blog – Joey Med | GLP-1 Telehealth Tampa FL